Sudarshan Pharma Industries Limited
BSE: SUDARSHAN · Specialty Chemicals
Snapshot
Unlock Sudarshan Pharma Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sudarshan Pharma Industries Ltd. is a specialty chemicals and pharmaceutical company that provides intermediates, active pharmaceutical ingredients (APIs), and generic formulations. The company operates through an outsourced supply model, serving healthcare institutions, government bodies, NGOs, and hospitals both in India and internationally.
Business Model
The company functions primarily as an aggregator and supply chain partner, outsourcing the manufacturing of chemicals and pharmaceutical formulations to provide end-to-end solutions for its clients. It generates revenue by supplying these products to diverse healthcare sectors and institutional buyers.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued demand for generic pharmaceutical formulations within institutional and government healthcare channels.
Key Risks
- Supply Chain Dependency. The company's reliance on outsourced manufacturing makes it vulnerable to quality control issues or supply disruptions from third-party vendors.
- Regulatory Compliance. Changes in pharmaceutical regulations or quality standards in India and international markets could impact the company's ability to supply its products.
- Intense Market Competition. The specialty chemicals and generic pharma sectors are highly competitive, which may exert pressure on profit margins.
- Institutional Client Concentration. Heavy reliance on government and NGO contracts exposes the company to risks associated with payment delays and changes in public procurement policies.
Start your research today
Unlock AI insights, financials, peers and live data on Sudarshan Pharma Industries Limited and 5,000+ companies — free.
Key Metrics
P/E
29.3×
Q2 FY27 · consolidated
EV/EBITDA
16.8x
Q2 FY27 · consolidated
NET PROFIT MARGIN
3.6%
Q2 FY27 · consolidated
DEBT TO EQUITY
2.0%
Q2 FY27 · consolidated
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sudarshan Pharma Industries LimitedSUDARSHAN | ₹895 Cr | 29.3× | 16.81 | — | 9.8% | 17.3% | 27.6% | +30.1% |
Jyoti Resins & Adhesives LimitedJYOTIRES | ₹1,021 Cr | 15.8× | 11.06 | 12.9% | 27.1% | 24.8% | 32.9% | -31.2% |
Indo AminesINDOAMIN | ₹899 Cr | 11.2× | 7.58 | 13.2% | 12.7% | 22.9% | 30.3% | -7.0% |
Sunshield Chemicals LimitedSUNSHIEL | ₹874 Cr | 23.0× | 13.75 | 13.1% | 13.8% | 20.9% | 26.3% | -3.6% |
Fairchem OrganicFAIRCHEMOR | ₹818 Cr | 57.3× | 25.19 | 0.1% | 7.1% | 5.1% | 7.8% | -14.1% |
Kronox Lab Sciences LimitedKRONOX | ₹721 Cr | 25.0× | 17.64 | 6.1% | 38.7% | 27.7% | 35.9% | +31.1% |
As of Q2 FY27
Financials
Sudarshan Pharma Industries Limited
BSE: SUDARSHAN · Specialty Chemicals
Snapshot
Unlock Sudarshan Pharma Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sudarshan Pharma Industries Ltd. is a specialty chemicals and pharmaceutical company that provides intermediates, active pharmaceutical ingredients (APIs), and generic formulations. The company operates through an outsourced supply model, serving healthcare institutions, government bodies, NGOs, and hospitals both in India and internationally.
Business Model
The company functions primarily as an aggregator and supply chain partner, outsourcing the manufacturing of chemicals and pharmaceutical formulations to provide end-to-end solutions for its clients. It generates revenue by supplying these products to diverse healthcare sectors and institutional buyers.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued demand for generic pharmaceutical formulations within institutional and government healthcare channels.
Key Risks
- Supply Chain Dependency. The company's reliance on outsourced manufacturing makes it vulnerable to quality control issues or supply disruptions from third-party vendors.
- Regulatory Compliance. Changes in pharmaceutical regulations or quality standards in India and international markets could impact the company's ability to supply its products.
- Intense Market Competition. The specialty chemicals and generic pharma sectors are highly competitive, which may exert pressure on profit margins.
- Institutional Client Concentration. Heavy reliance on government and NGO contracts exposes the company to risks associated with payment delays and changes in public procurement policies.
Start your research today
Unlock AI insights, financials, peers and live data on Sudarshan Pharma Industries Limited and 5,000+ companies — free.
Key Metrics
P/E
29.3x
Q2 FY27 · consolidated
EV/EBITDA
16.8x
Q2 FY27 · consolidated
NET PROFIT MARGIN
3.6%
Q2 FY27 · consolidated
DEBT TO EQUITY
2.0%
Q2 FY27 · consolidated
Peers · Specialty Chemicals
As of Q2 FY27